BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 37248615)

  • 1. Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer.
    Dey A; Mitra A; Pathak S; Prasad S; Zhang AS; Zhang H; Sun XF; Banerjee A
    Technol Cancer Res Treat; 2023; 22():15330338231178403. PubMed ID: 37248615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for personalized medicine in GI cancers.
    Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
    Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack.
    Henderson D; Ogilvie LA; Hoyle N; Keilholz U; Lange B; Lehrach H;
    Biotechnol J; 2014 Sep; 9(9):1104-14. PubMed ID: 25074435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omics sciences and precision medicine in glioblastoma.
    Micheletti C; Bonetti G; Madeo G; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Manganotti P; Caruso P; Bernini A; Fulcheri E; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
    Clin Ter; 2023; 174(Suppl 2(6)):77-84. PubMed ID: 37994751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment.
    Jahanafrooz Z; Mosafer J; Akbari M; Hashemzaei M; Mokhtarzadeh A; Baradaran B
    J Cell Physiol; 2020 May; 235(5):4153-4166. PubMed ID: 31647128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized cancer treatment and the myth of KRAS wild-type colon tumors.
    Parsons BL; Myers MB
    Discov Med; 2013 Apr; 15(83):259-67. PubMed ID: 23636143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward Personalized Cancer Treatment: From Diagnostics to Therapy Monitoring in Miniaturized Electrohydrodynamic Systems.
    Khondakar KR; Dey S; Wuethrich A; Sina AA; Trau M
    Acc Chem Res; 2019 Aug; 52(8):2113-2123. PubMed ID: 31293158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive biomarkers for personalized medicine in breast cancer.
    Rodrigues-Ferreira S; Nahmias C
    Cancer Lett; 2022 Oct; 545():215828. PubMed ID: 35853538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
    Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
    World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
    Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
    BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance.
    Hall MJ; Morris AM; Sun W
    Am Soc Clin Oncol Educ Book; 2018 May; 38():220-230. PubMed ID: 30231337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present and future of personalized medicine in adult genitourinary tumors.
    Ciccarese C; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Conti A; Tortora G; Cascinu S; Montironi R
    Future Oncol; 2015; 11(9):1381-8. PubMed ID: 25952784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine.
    Mouillet-Richard S; Cazelles A; Sroussi M; Gallois C; Taieb J; Laurent-Puig P
    Clin Cancer Res; 2024 Jun; 30(11):2351-2358. PubMed ID: 38564259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chasing the personalized medicine dream through biomarker validation in colorectal cancer.
    Patil H; Saxena SG; Barrow CJ; Kanwar JR; Kapat A; Kanwar RK
    Drug Discov Today; 2017 Jan; 22(1):111-119. PubMed ID: 27693431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapy and Personalized Medicine.
    Saeed RF; Awan UA; Saeed S; Mumtaz S; Akhtar N; Aslam S
    Cancer Treat Res; 2023; 185():177-205. PubMed ID: 37306910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
    Sinicrope FA; Okamoto K; Kasi PM; Kawakami H
    Clin Gastroenterol Hepatol; 2016 May; 14(5):651-8. PubMed ID: 26872400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
    Music M; Prassas I; Diamandis EP
    Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.